ESR1 and breast carcinoma: The molecular basis for how ER and HER2 blockade leads to Notch activation is only partially understood and will require further research, but the notion that Notch signaling is secondarily upregulated following the primary therapies for ER- and HER2-positive breast cancer may suggest that combination therapies, involving Notch inhibition, may be an interesting future avenue to explore.